Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

Abscopal Outcomes: Reflections on Distant Effects.

Meyskens FL Jr.

Pract Radiat Oncol. 2019 May 16. pii: S1879-8500(19)30127-4. doi: 10.1016/j.prro.2019.05.002. [Epub ahead of print] No abstract available.

PMID:
31103714
2.

Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma.

Yuan TA, Lu Y, Edwards K, Jakowatz J, Meyskens FL, Liu-Smith F.

Int J Environ Res Public Health. 2019 Mar 13;16(6). pii: E908. doi: 10.3390/ijerph16060908.

3.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS.

J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185.

4.

Oxidative stress and antioxidants in the pathophysiology of malignant melanoma.

Obrador E, Liu-Smith F, Dellinger RW, Salvador R, Meyskens FL, Estrela JM.

Biol Chem. 2019 Apr 24;400(5):589-612. doi: 10.1515/hsz-2018-0327. Review.

5.

12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma.

Laquer V, Dellinger RW, Mannering I, Garcia AG, Abraham V, Pavlis J, Liu-Smith F, De Feraudy S, Meyskens FL Jr, Kelly KM.

J Am Acad Dermatol. 2018 Dec;79(6):1152-1153. doi: 10.1016/j.jaad.2018.05.1251. Epub 2018 Jun 11. No abstract available.

PMID:
29902547
6.

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.

Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL Jr, Liu-Smith F, Filipp FV.

BMC Syst Biol. 2018 Apr 4;12(1):33. doi: 10.1186/s12918-018-0554-1.

7.

A Case-Control Study of the Genetic Variability in Reactive Oxygen Species-Metabolizing Enzymes in Melanoma Risk.

Yuan TA, Yourk V, Farhat A, Ziogas A, Meyskens FL, Anton-Culver H, Liu-Smith F.

Int J Mol Sci. 2018 Jan 14;19(1). pii: E242. doi: 10.3390/ijms19010242.

8.

Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis.

Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL Jr, Andresen BT, Huang Y.

Cancer Prev Res (Phila). 2017 Oct;10(10):598-606. doi: 10.1158/1940-6207.CAPR-17-0132. Epub 2017 Aug 15.

9.

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS.

NPJ Breast Cancer. 2016 Aug 10;2:16024. doi: 10.1038/npjbcancer.2016.24. eCollection 2016.

10.

Redox-Redux and NADPH Oxidase (NOX): Even More Complicated than We Thought it Might Be.

Meyskens FL Jr, Liu-Smith F.

J Invest Dermatol. 2017 Jun;137(6):1208-1210. doi: 10.1016/j.jid.2017.01.019. Review.

11.

Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure.

Liu-Smith F, Farhat AM, Arce A, Ziogas A, Taylor T, Wang Z, Yourk V, Liu J, Wu J, McEligot AJ, Anton-Culver H, Meyskens FL.

J Am Acad Dermatol. 2017 Mar;76(3):499-505.e3. doi: 10.1016/j.jaad.2016.08.027. Epub 2016 Oct 26.

12.

What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA.

Meyskens FL Jr.

J Natl Cancer Inst. 2016 Dec 16;108(12). pii: djw252. Print 2016 Dec. No abstract available.

PMID:
27986883
13.

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.

Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL.

Trials. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9.

14.

Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity.

Uchio E, Meyskens FL, Wang PH.

Cancer Prev Res (Phila). 2016 Oct;9(10):777-778. Epub 2016 Jul 18. No abstract available.

15.

Measuring Redox Status of Melanoma Cells.

Liu-Smith F, Krasieva TB, Liu J, Liu J, Meyskens FL Jr.

Methods Mol Biol. 2016 Apr 10. [Epub ahead of print]

16.

Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma.

Liu-Smith F, Meyskens FL.

Mol Nutr Food Res. 2016 Jun;60(6):1264-74. doi: 10.1002/mnfr.201500822. Epub 2016 Mar 21. Review.

17.

Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells.

Dellinger RW, Meyskens FL Jr.

Methods Mol Biol. 2016 Jan 20. [Epub ahead of print]

PMID:
26786882
18.

Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals.

Meyskens FL Jr.

Cancer Prev Res (Phila). 2016 Jan;9(1):11-2. doi: 10.1158/1940-6207.CAPR-15-0401. Epub 2015 Dec 23. No abstract available.

19.

Cancer Prevention: Obstacles, Challenges and the Road Ahead.

Meyskens FL Jr, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS.

J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv309. doi: 10.1093/jnci/djv309. Print 2016 Feb. Review.

20.

Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group.

Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr.

J Clin Oncol. 2016 Jan 10;34(2):186-93. doi: 10.1200/JCO.2015.63.5979. Epub 2015 Nov 2.

Supplemental Content

Loading ...
Support Center